NEW YORK (GenomeWeb News) — Certain members of Tripos’ management team may consider buying the firm’s Discovery Research business if bids by Provid Pharmaceuticals or other parties fall through, the company said last week.
 
Tripos made its remarks as the company said that fourth-quarter revenues declined 8 percent as R&D spending fell 35 percent and loss narrowed 46 percent.
 
Total receipts for the three months ended Dec. 31, 2006, fell to $6.7 million from $7.2 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.